RCUS Arcus Biosciences, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Arcus Biosciences, Inc. (RCUS) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 25, 2026, a 10-Q quarterly report filed on May 5, 2026, an 8-K current report filed on June 12, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Arcus Biosciences, Inc. (RCUS) (SEC CIK 1724521), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Development and commercialization of investigational pharmaceutical products in immuno-oncology
- • No new products or segments introduced; increased emphasis on regulatory, pricing, and healthcare reform risks in U.S. markets
Risk Factors
- • Regulatory risk from Gilead collaboration amendment causing revenue catch-up of $143M in 2025, impacting timing and recognition of license income
- • Macroeconomic exposure to collaboration funding variability, e.g., Taiho option revenue dropped from $15M in 2024 to $7M in 2025
Management Discussion & Analysis
- • No product sales revenue; all revenue from license, collaboration, and development services agreements
- • License and development services revenue recognized based on percentage completion of R&D obligations
Annual Reports Archive10-K
AI-powered analysis of Arcus Biosciences, Inc. (RCUS) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Arcus Biosciences, Inc. (RCUS) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Arcus Biosciences, Inc. (RCUS) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $112.0M | $117.0M | $51.0M | $33.0M |
| Operating Income | -$280.0M | -$340.0M | -$330.0M | -$386.0M |
| Net Income | -$267.0M | -$307.0M | -$283.0M | -$353.0M |
| Op. Margin | -250.0% | -290.6% | -647.1% | -1169.7% |
| Net Margin | -238.4% | -262.4% | -554.9% | -1069.7% |
| Balance Sheet | ||||
| Total Assets | $1.3B | $1.1B | $1.1B | $1.1B |
| Equity | $657.0M | $462.0M | $485.0M | $631.0M |
| ROE | -40.6% | -66.5% | -58.4% | -55.9% |
Source: XBRL financial data from Arcus Biosciences, Inc. (RCUS) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Jun 12, 2026 | — | — | — |
8-K | May 5, 2026 | — | — | — |
10-Q | May 5, 2026 | Mar 31, 2026 | — | |
8-K | Apr 20, 2026 | — | — | — |
8-K | Mar 23, 2026 | — | — | — |
8-K | Feb 25, 2026 | — | Analysis | — |
10-K | Feb 25, 2026 | Dec 31, 2025 | Analysis | |
8-K | Dec 18, 2025 | — | — | |
8-K | Dec 12, 2025 | — | — | |
10-Q | Oct 28, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 25, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-K | Feb 21, 2024 | Dec 31, 2023 | — | |
SC 13G | Feb 9, 2024 | — | — | |
SC 13G | Jan 24, 2024 | — | — | |
10-Q | Nov 7, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 7, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-K | Feb 28, 2023 | Dec 31, 2022 | — | |
SC 13G | Feb 9, 2023 | — | — | |
10-Q | Nov 2, 2022 | Sep 30, 2022 | — |
Frequently Asked Questions
What are the latest RCUS SEC filings in 2026?
Arcus Biosciences, Inc. (RCUS) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on June 12, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did RCUS file its most recent 10-K annual report?
Arcus Biosciences, Inc. (RCUS) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view RCUS 10-Q quarterly reports?
Arcus Biosciences, Inc. (RCUS)'s most recent 10-Q quarterly report was filed on May 5, 2026. SignalX displays every RCUS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has RCUS filed recently?
Arcus Biosciences, Inc. (RCUS)'s most recent 8-K was filed on June 12, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find RCUS insider trading activity (Form 4)?
SignalX aggregates every RCUS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does RCUS file with the SEC?
Arcus Biosciences, Inc. (RCUS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RCUS filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Arcus Biosciences, Inc. (RCUS).
What is RCUS's SEC CIK number?
Arcus Biosciences, Inc. (RCUS)'s SEC CIK (Central Index Key) number is 1724521. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1724521 to look up all RCUS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find RCUS return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Arcus Biosciences, Inc. (RCUS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Arcus Biosciences, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 61+ filings.